Literature DB >> 22075066

Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients.

Marcello Govoni1, Stefano Bombardieri, Alessandra Bortoluzzi, Luisa Caniatti, Cinzia Casu, Fabrizio Conti, Salvatore De Vita, Andrea Doria, Ilaria Farina, Gianfranco Ferraccioli, Elisa Gremese, Elisa Mansutti, Marta Mosca, Melissa Padovan, Matteo Piga, Angela Tincani, Maria Rosaria Tola, Paola Tomietto, Marco Taglietti, Francesco Trotta, Guido Valesini, Margherita Zen, Alessandro Mathieu.   

Abstract

OBJECTIVE: To analyse risk factors and comorbidities potentially associated with CNS involvement in a large cohort of Italian patients affected by SLE.
METHODS: A number of generic (not strictly SLE related) and specific (disease related) risk factors to which all patients have been exposed in the span of 5 years before the first neuropsychiatric (NP) event or before the last available observation were checked for and their distribution was analysed in 959 SLE patients with and without NP involvement; all the first NP events that occurred in a time frame of 10 years were recorded and categorized as SLE related or SLE unrelated.
RESULTS: Three hundred and twenty-six SLE patients with and 633 SLE patients without NP manifestations were included in the study. A total of 469 NP events were recorded. Headache (26.1%), cerebrovascular events (22.7%), mood disorders (8.9%), seizures (14.4%) and cognitive dysfunctions (9.5%) were the most frequent SLE-related NP events. More risk factors [mean 4.52 (2.44) vs 3.73 (2.01); P < 0.0001] were observed in patients with than without NP involvement. Overall, aPLs, LA and APS were factors more strongly associated with NP involvement.
CONCLUSIONS: In SLE, NP involvement and aPLs were confirmed as closely related. Furthermore, other modifiable generic risk factors, such as hypertension, carotid vasculopathy and dyslipidaemia, appeared to be related to the occurrence of cerebral vascular accident (CVA) and cognitive dysfunctions, suggesting the need for a more intensive preventive strategy to optimize the management of NP lupus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075066     DOI: 10.1093/rheumatology/ker310

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  23 in total

1.  Libman-Sacks endocarditis and embolic cerebrovascular disease.

Authors:  Carlos A Roldan; Wilmer L Sibbitt; Clifford R Qualls; Rex E Jung; Ernest R Greene; Charles M Gasparovic; Reyaad A Hayek; Gerald A Charlton; Kendall Crookston
Journal:  JACC Cardiovasc Imaging       Date:  2013-09

Review 2.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions.

Authors:  Noa Schwartz; Ariel D Stock; Chaim Putterman
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

Review 3.  Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature.

Authors:  Fabrizio Conti; Fulvia Ceccarelli; Carlo Perricone; Laura Massaro; Enrica Cipriano; Viviana Antonella Pacucci; Simona Truglia; Francesca Miranda; Francesca Morello; Cristiano Alessandri; Francesca Romana Spinelli; Guido Valesini
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 4.  Tailored treatment strategies and future directions in systemic lupus erythematosus.

Authors:  Dionysis Nikolopoulos; Lampros Fotis; Ourania Gioti; Antonis Fanouriakis
Journal:  Rheumatol Int       Date:  2022-04-21       Impact factor: 3.580

Review 5.  Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review.

Authors:  M Zen; M Gatto; M Domeneghetti; L Palma; E Borella; L Iaccarino; L Punzi; A Doria
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

6.  Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity.

Authors:  L Carli; C Tani; F Querci; A Della Rossa; S Vagnani; C Baldini; R Talarico; A d'Ascanio; R Neri; A G Tavoni; S Bombardieri; M Mosca
Journal:  Clin Rheumatol       Date:  2013-03-03       Impact factor: 2.980

Review 7.  Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.

Authors:  Giuseppe Turchetti; Jinoos Yazdany; Ilaria Palla; Edward Yelin; Marta Mosca
Journal:  Clin Exp Rheumatol       Date:  2012-10-16       Impact factor: 4.473

Review 8.  Diagnosis and management of neuropsychiatric SLE.

Authors:  John G Hanly
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

Review 9.  Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.

Authors:  Hélène Jeltsch-David; Sylviane Muller
Journal:  Nat Rev Neurol       Date:  2014-09-09       Impact factor: 42.937

10.  Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients.

Authors:  Eleni I Kampylafka; Haralampos Alexopoulos; Michalis L Kosmidis; Demosthenes B Panagiotakos; Panayiotis G Vlachoyiannopoulos; Marinos C Dalakas; Haralampos M Moutsopoulos; Athanasios G Tzioufas
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.